- Previous Close
7.86 - Open
7.94 - Bid --
- Ask --
- Day's Range
7.94 - 8.24 - 52 Week Range
6.40 - 9.90 - Volume
9,689 - Avg. Volume
2,168 - Market Cap (intraday)
111.679M - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-1.70 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.20
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
www.maatpharma.comRecent News: MAAT.PA
View More
Performance Overview: MAAT.PA
Trailing total returns as of 12/9/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAAT.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAAT.PA
View MoreValuation Measures
Market Cap
109.18M
Enterprise Value
98.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
40.09
Price/Book (mrq)
5.33
Enterprise Value/Revenue
44.41
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.99%
Return on Equity (ttm)
-84.85%
Revenue (ttm)
2.57M
Net Income Avi to Common (ttm)
-24.14M
Diluted EPS (ttm)
-1.70
Balance Sheet and Cash Flow
Total Cash (mrq)
31.15M
Total Debt/Equity (mrq)
67.04%
Levered Free Cash Flow (ttm)
-8.77M
Research Analysis: MAAT.PA
View MoreCompany Insights: MAAT.PA
MAAT.PA does not have Company Insights